🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 3 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/01/2026 23,31 23,35 20,59 21,77 -6,53% 11,84% 2.085.400
02/01/2026 23,81 23,99 22,72 23,29 -2,27% 5,35% 1.026.000
31/12/2025 23,38 24,16 23,11 23,83 +2,58% 4,46% 1.715.200
30/12/2025 23,27 23,52 22,60 23,23 -0,43% 3,95% 2.070.100
29/12/2025 22,96 23,62 22,66 23,33 +1,04% 4,18% 957.900
26/12/2025 23,16 23,31 22,65 23,09 -0,13% 2,85% 694.900
24/12/2025 22,83 23,16 22,53 23,12 +1,81% 2,76% 444.800
23/12/2025 23,07 23,49 22,51 22,71 -2,20% 4,25% 783.300
22/12/2025 21,80 23,35 21,80 23,22 +5,64% 7,11% 1.480.600
19/12/2025 21,98 22,44 21,87 21,98 -0,05% 2,59% 4.507.900
18/12/2025 22,31 22,70 21,81 21,99 -1,30% 3,97% 1.175.900
17/12/2025 22,35 22,49 21,87 22,28 +0,36% 2,76% 1.984.400
16/12/2025 21,62 22,41 21,27 22,20 +1,32% 5,27% 2.995.800
15/12/2025 21,51 22,01 20,81 21,91 +1,76% 5,58% 3.803.900
12/12/2025 21,15 24,00 20,35 21,53 -14,36% 17,26% 7.424.500
11/12/2025 25,71 26,10 25,10 25,14 -1,02% 3,89% 1.148.800
10/12/2025 25,04 26,02 24,75 25,40 +1,32% 5,07% 2.406.900
09/12/2025 25,78 26,40 25,01 25,07 -2,83% 5,41% 1.513.600
08/12/2025 25,72 26,25 25,43 25,80 +1,38% 3,21% 1.300.400
05/12/2025 25,44 25,80 24,67 25,45 +0,75% 4,44% 1.275.500
04/12/2025 25,31 25,87 24,32 25,26 -1,44% 6,12% 1.884.400
03/12/2025 25,62 26,40 25,33 25,63 +0,79% 4,18% 2.164.000
02/12/2025 25,76 26,35 24,77 25,43 -2,57% 6,13% 2.719.600
01/12/2025 25,56 26,27 25,12 26,10 +0,00% 4,50% 2.620.200
28/11/2025 25,81 26,32 25,62 26,10 +2,11% 2,73% 676.000
26/11/2025 24,10 26,04 24,00 25,56 +5,27% 8,44% 1.975.600
25/11/2025 23,28 24,95 22,85 24,28 +4,75% 9,02% 3.416.800
24/11/2025 22,18 23,38 21,90 23,18 +5,12% 6,65% 2.229.700
21/11/2025 21,19 22,49 20,82 22,05 +3,86% 7,88% 2.031.700
20/11/2025 20,67 21,55 20,50 21,23 +5,00% 5,08% 2.128.200